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BACKGROUND: The Hybrid Capture II high-risk human papillomavirus (hrHPV) DNA test is a US Food and
Drug Administration-approved nucleic acid hybridization assay using chemiluminescence for the semiquan-
titative detection of hrHPV in cervical samples. Patient samples and controls are used to calculate results
as negative for hrHPV if <1.0, positive for hrHPV if >2.5, and ‘‘equivocal’’ if between 1.0 and 2.5. METHODS:
The authors reported on the cervical histologic results of 209 patients demonstrating ‘‘equivocal’’ results
for hrHPV from SurePath (204 patients) or ThinPrep (5 patients) vials, and compared patients in this
cohort with atypical squamous cells of undetermined significance (ASC-US) cytology on the index cervical
Papanicolaou (Pap) test (Group 1; n ¼ 148 patients) with a patient cohort demonstrating unequivocal posi-
tive hrHPV test results (Group 2; n ¼ 148 patients). The chemiluminescence intensity of hrHPV tests from
patients in Group 2 were correlated with the presence and severity of dysplasia on subsequent histologic
results, and patients were thereby stratified for their subsequent risk of cervical intraepithelial neoplasia
(CIN) types II/III. RESULTS: Approximately 97% of hrHPV tests demonstrating ‘‘equivocal’’ results were
found to be positive at the time of retesting, and 15% of biopsied cases demonstrated CIN II or III. Results
of follow-up histology after an ASC-US diagnosis, expressed as a percentage of the biopsied cohort, were:
CIN II/III: 16.5% in Group 1 and 22.4% in Group 2; CIN I: 27% in Group 1 and 23.5% in Group 2; and negative:
56.5% in Group 1 and 54.1% in Group 2. Chemiluminescence intensity did not appear to be correlated with
the severity of dysplasia. CONCLUSIONS: The percentage of high-grade CIN in the ‘‘equivocal’’ hrHPV
cohort is highly significant and therefore the management of these patients should be similar to the
unequivocally positive population. After an unequivocal positive hrHPV test, the hrHPV chemiluminescence
intensity does not appear to further predict the rate of high-grade CIN. Cancer (Cancer Cytopathol)
2010;118:209–17. VC 2010 American Cancer Society.
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High-risk types of human papillomavirus
(hrHPV) have been implicated in the vast majority of
cases of high-grade cervical dysplasia and cervical carci-
noma,1 and hrHPV testing has emerged as a highly sen-
sitive test for the presence of cervical neoplasia.2 A wide
variety of tests are currently available for the detection
of hrHPV. Although the variety of available tests pro-
vides many options for laboratories using a hrHPV
test, it is important that laboratories use analytically as
well as clinically validated assays.3
Unlike low-risk types of HPV, in which the HPV
genome is typically maintained in a nonintegrated (episo-
mal) form, hrHPV has the ability to integrate into the
host genome,4 ultimately leading to the overexpression of
E6 and E7 viral genes. These genes may act to transform
and immortalize cells via protein binding and inactivation
of p53 and pRB tumor suppressor genes.5-7 Although
hrHPV is implicated in virtually all cases of cervical carci-
noma, it most often manifests as a self-limited resolving
infection, with approximately 70% of cases resolved after
1 year and 90% of cases resolved after 2 years.8 Because
the incidence of hrHPV is much higher than that of cervi-
cal neoplasia, testing for hrHPV has not been shown to be
as cost-effective as a stand-alone primary screening test in
the general population.9 Rather, as concluded from data
generated by the Atypical Squamous Cells of Undeter-
mined Significance/Low-Grade Squamous Intraepithelial
Lesion Triage Study (the ALTS trial), hrHPV testing has
been established as a primary triage test for cervical cytol-
ogy specimens with atypical squamous cells of undeter-
mined significance (ASC-US) results.10,11 An additional
indication for hrHPV testing that has emerged more
recently is as primary screening for women aged >30
years who have had a normal Papanicolaou (Pap) test.12,13
This is because of the finding that women in this sub-
group have a lower incidence of hrHPV infection and a
higher incidence of cervical dysplasia or carcinoma when
HPV is present compared with patients aged <30
years.14,15
The Qiagen Hybrid Capture II (HC II; Qiagen, Va-
lencia, CA) test is the most commonly used test for
hrHPV and, along with the Cervista hrHPV test (Holo-
gic, Marlborough, MA), is 1 of 2 available testing meth-
ods approved by the US Food and Drug Administration
(FDA).16 Although the HC II has been approved when
used with Qiagen Standard Transport Medium (STM)
and ThinPrep specimens (transported in PreservCyt, both
from Hologic), laboratories may use the HC II test with
other liquid-based transport media (eg, SurePath; TriPath
Imaging, Inc, Burlington, NC) provided appropriate in-
house validation studies have been completed.17 The HC
II test has demonstrated similar performance in detecting
high-grade dysplasia regardless of whether SurePath or
ThinPrep specimens are used.18 The HC II test uses signal
amplification chemiluminescence that provides an output
in relative light units (RLUs). The patient samples are run
with appropriate positive and negative controls that are
used to validate results and calculate a cutoff value (CO),
such that final testing output is expressed as a ratio of
RLU to CO (RLU/CO). The CO is calculated by averag-
ing the RLU values of triplicate high-risk samples (high-
risk calibrators comprised of HPV type 16 [HPV 16]
DNA). An RLU/CO value of >1.0 is deemed positive,
but if the initial test falls between 1.0 and 2.5 RLU/CO,
the value is considered to be within an initial ‘‘equivocal’’
range, and per FDA labeling, the test must be repeated. If
either of 2 subsequent tests fall on or above 1.0 RLU/CO,
the test is then deemed positive. If 2 subsequent tests fall
below 1.0, the final result is then determined to be nega-
tive for HPV.
To the best of our knowledge, few studies to date
have examined the subsequent cervical histology from
patients whose cervical hrHPV tests have shown ‘‘equivo-
cal’’ results.19 In addition, to our knowledge only a few
studies to date have examined the relation between the
level of hrHPV found in cervical specimens and the inci-
dence of cervical dysplasia detected on follow-up histol-
ogy.20,21 Because the HC II is a qualitative as well as
semiquantitative test, the RLU/CO value may be used as a
surrogate for the hrHPV level (ie, copy number). In this
study, we further examined the relation between the




The study examined all hrHPV tests over an 18-month
period in our laboratory, corresponding to a total volume
of 5297 hrHPV tests. During this time period, 72,056
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liquid-based Pap tests were completed at the Massachu-
setts General Hospital, of which>97% represented Sure-
Path specimens. hrHPV tests that were initially reported
to be within the equivocal range were selected for review
of subsequent hrHPV test results, including correspond-
ing cytopathologic and histopathologic results over a 2-
year follow-up period. A subset of equivocal hrHPV tests
corresponding to Pap tests demonstrating ASC-US cytol-
ogy were reviewed and compared with a numerically
matched cohort of patients who had ASC-US cytology
and an associated unequivocal positive hrHPV test. This
latter group was selected based on consecutive cases tested
for hrHPV during the study time period (n ¼ 148
patients).
High-Risk HPV Assay
The HC II hrHPVAssay is an in vitro nucleic acid hybrid-
ization assay that detects 13 high-risk types of HPV (spe-
cifically, types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68). The assay was performed as reported previ-
ously.19 Briefly, an aliquot of residual Pap test preservative
medium from either a SurePath or ThinPrep Pap test was
incubated with a probe cocktail containing hrHPV-spe-
cific RNA molecules, performed on 96-well plates. After
hybridization, antibodies conjugated with alkaline phos-
phatase and specific for RNA:DNA hybrids were added,
followed by a chemiluminescent substrate. Results were
quantified via luminometer. Positive and negative con-
trols were comprised of HPV-16 DNA and non-hrHPV
DNA, respectively. SurePath samples were prepared for
the HC II assay as previously described.17 ThinPrep sam-
ples were prepared for the HC II assay as per the manufac-
turer’s FDA-approved protocol. Results were reported as




Cytopathologic and histopathologic results were based on
a review of cytology and histology reports generated dur-
ing the 22-month time frame of the study and extended to
a period of up to 2 years after the index Pap test on which
the hrHPV test was based. Histopathological results of
cervical intraepithelial neoplasia (CIN) type II (CIN II) or
CIN III were re-reviewed and confirmed by 2 pathologists
for this study.
RESULTS
Cytologic and Histologic Results of All
Equivocal Tests
The total cohort of patients whose hrHPV tests demon-
strated ‘‘equivocal’’ results was 209 (4%) of 5297 total
tests over the 18-month period of study. These tests were
found to be positive for hrHPV at the time of retesting in
202 of 209 (97%) cases (Table 1). Of the 209 initial
equivocal hrHPV tests, 204 were obtained from SurePath
samples (final positive, 198 of 204 tests [97.1%]) and 5
were obtained from ThinPrep samples (final positive, 4 of
5 tests [80%]). Corresponding cytologic diagnoses for the
















CIN I CIN II CIN III Invasive
ADC
NILM 37 33 8 7 (88%) 1 (13%) 0 0 0
ASC-US 148 145 85 48 (56.5%) 23 (27%) 8 (9.4%) 5 (5.9%) 1 (1.2%)
ASC-H 13 13 11 4 (36.4%) 4 (36.4%) 0 3 (27.2%) 0
LSIL 9 9 6 3 (50%) 3 (50%) 0 0 0
HSIL 1 1 1 1 (100%) 0 0 0 0
AGC-US 1 1 1 1 (100%) 0 0 0 0
Total 209 202 112 64 (57.1%) 31 (27.7%) 8 (7.1%) 8 (7.1%) 1 (0.9%)
hrHPV indicates high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia; ADC, adenocarcinoma; NILM, negative for intraepithelial lesion or
malignancy; ASC-US, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepi-
thelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; AGC-US, atypical glandular cells of undeter-
mined significance.
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209 equivocal cases (Table 1) were negative or reactive for
intraepithelial lesion or malignancy (NILM) in 37 cases
(18%); ASC-US in 148 cases (71%); atypical squamous
cells, cannot exclude high-grade squamous intraepithelial
lesion (ASC-H) in 13 cases (6%); low-grade squamous
intraepithelial lesion (LSIL) in 9 cases (4%); high-grade
squamous intraepithelial lesion (HSIL) in 1 case (0.5%);
and atypical glandular cells in 1 case (0.5%). Follow-up
histology was available for 112 of the 209 cases (54%)
(Table 1) (Fig. 1). Figure 1 shows data expressed as per-
centages of the total number of equivocal tests (NILM,
31%; CIN I, 15%; and CIN II/III or invasive adenocarci-
noma, 8%) and percentages of the biopsied cohort
(NILM, 57%; CIN I, 28%; CIN II/III or invasive adeno-
carcinoma, 15%). Of the 7 tests that were found to be
negative for hrHPV at the time of retest, 6 had no histo-
logic follow-up and 1 demonstrated CIN I on histologic
follow-up (originally ASC-US on cytology). The 5 Thin-
Prep specimens all demonstrated ASC-US results with no
available follow-up histology.
Histologic Results of Equivocal and
Nonequivocal Tests With ASC-US Cytology
Histologic results from the cohort of patients with an
equivocal hrHPV test demonstrating ASC-US on the cor-
responding Pap test were compared with histologic results
from a numerically matched cohort of patients with a
unequivocal hrHPV test and ASC-US demonstrated on a
corresponding Pap test (Figs. 2 and 3). Figure 2 shows
data expressed as percentages of the total number of
hrHPV tests. For patients with an equivocal hrHPV test,
follow-up biopsy data indicated NILM in 32.4%, CIN I
in 15.5%, and CIN II/III or invasive adenocarcinoma in
9.5%. For patients with an unequivocal positive hrHPV
test, follow-up biopsy data demonstrated NILM in
35.8%, CIN I in 15.5%, and CIN II/III in 14.9%. Figure
FIGURE 1. Corresponding histologic diagnoses of samples
with equivocal high-risk human papillomavirus (hrHPV) tests
are shown (2-year follow-up [F/U]). (A) Negative or reactive
for intraepithelial lesion or malignancy and cervical intraepi-
thelial neoplasia type I (CIN I) or CIN II-III/adenocarcinoma
(ADC) results are shown as percentages of the referenced
total study group. (B) The results from Panel A are presented
as percentages of the biopsied cohort.
FIGURE 2. Corresponding histologic diagnoses of samples
with equivocal high-risk human papillomavirus (hrHPV) tests
or unequivocal positive hrHPV tests (2-year follow-up [F/U])
after a cytologic diagnosis of atypical squamous cells of
undetermined significance are shown. (A) Negative or reac-
tive for intraepithelial lesion or malignancy (NILM), cervical
intraepithelial neoplasia type I (CIN I), CIN II, CIN III, and inva-
sive adenocarcinoma (ADC) or no follow-up results are
expressed as a percentage of the total cohort after an equiv-
ocal hrHPV test. (B) NILM, CIN I, CIN II, or CIN III or no fol-
low-up results are expressed as a percentage of the total
cohort after an unequivocal positive hrHPV test. HSIL indi-
cates high-grade squamous intraepithelial lesion; þ, positive;
SIL, squamous intraepithelial lesion.
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3 shows data expressed as percentages of the biopsied
cohort. For patients with an equivocal hrHPV test, fol-
low-up biopsy data demonstrated NILM in 56.5%, CIN
I in 27%, and CIN II/III or invasive adenocarcinoma in
16.5%. For patients with an unequivocal positive hrHPV
test, follow-up biopsy data indicated NILM in 35.8%,
CIN I in 15.5%, and CIN II/III in 14.9%.
Chemiluminescence Intensity of hrHPV
Tests Based on Histologic Diagnosis
The chemiluminescence intensity of unequivocal positive
hrHPV tests from patients found to have ASC-US cytol-
ogy on a corresponding Pap test was correlated with the
follow-up histologic results (Fig. 4). Average chemilumi-
nescence intensity (shown as RLU/CO) when correlated
with follow-up histology was 281 in negative cases, 153 in
CIN I cases, 191 in CIN II cases, 190 in CIN III cases,
and 313 in no follow-up cases. The differences among the
groups were not found to be statistically significant (inde-
pendent group Student t test). The calculated 2-tailed P
values were CIN II or CIN III versus CIN I, P ¼ .61;
CIN II or CIN III versus NILM, P¼ .37; and CIN I ver-
sus NILM, P¼ .19.
Histologic Results Based on hrHPV Test
Chemiluminescence Intensity
Follow-up histology corresponding to patients found to
have ASC-US on cytology and a concomitant non-
equivocal positive hrHPV test were correlated with
chemiluminescence intensity. The median hrHPV chemi-
luminescence intensity of 148 cases was 61.54 RLU/CO.
Figure 5 shows the resulting follow-up histology of
patients corresponding to those whose RLU/CO value
was below the median (range, 2.74-57.71 RLU/CO) or
above the median (range, 65.36-2361.88 RLU/CO). The
follow-up histology of samples corresponding to hrHPV
tests with chemiluminescence intensity that was below the
median was no follow-up in 29.7% of samples, negative
for dysplasia in 37.8% of samples, CIN I in 16.2% of
samples, or CIN II/III in 16.2% of samples. The follow-
up histology of samples corresponding to hrHPV tests
with chemiluminescence intensity that was above the
FIGURE 3. Corresponding histologic diagnoses of samples
with equivocal high-risk human papillomavirus (hrHPV) tests
or unequivocal positive hrHPV tests (2-year follow-up) after a
cytologic diagnosis of atypical squamous cells of undeter-
mined significance are shown. (A) Negative or reactive for
intraepithelial lesion or malignancy (NILM), cervical intraepi-
thelial neoplasia type I (CIN I), CIN II, CIN III, or invasive ade-
nocarcinoma (ADC) results are expressed as a percentage of
the biopsied cohort after an equivocal hrHPV test. (B) NILM,
CIN I, CIN II, or CIN III results are expressed as a percentage
of the biopsied cohort after an unequivocal positive hrHPV
test. HSIL indicates high-grade squamous intraepithelial
lesion; þ, positive; SIL, squamous intraepithelial lesion.
FIGURE 4. Corresponding relative light units (RLU)/cutoff
value (CO) ratios of high-risk human papillomavirus tests
from samples demonstrating atypical squamous cells of
undetermined significance on cervical cytology and corre-
lated with follow-up cervical biopsies determined to be nega-
tive or reactive for intraepithelial lesion or malignancy
(NILM), cervical intraepithelial neoplasia type I (CIN I), CIN II,
and CIN III are shown.
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median was no follow-up in 37.8% of samples, negative
for displasia in 33.8% of samples, CIN I in 14.9% of sam-
ples, or CIN II/III in 13.5% of samples. Figure 6 shows
the same 2 groups expressed as a percentage of the biop-
sied cohort. The available follow-up histology of samples
corresponding to hrHPV tests with RLU/CO values
>1000 (n¼ 19 samples) were NILM in 7 samples (37%),
CIN I in 7 samples (37%), or CIN II/III in 5 samples
(26%). Figure 7 shows the histologic follow-up when the
groups were divided into 4 equal subsets based on chemi-
luminescence intensity.
DISCUSSION
The main objectives of the current study were 1) to pro-
vide 2-year histologic follow-up for the assessment of pa-
thology associated with equivocal hrHPV results; 2)
compare follow-up dysplasia rates after ASC-US Pap test
results and equivocal hrHPV tests with dysplasia rates in a
similar group of patients with unequivocal positive
hrHPV results; and 3) correlate the chemiluminescent in-
tensity of a positive HC II hrHPV test with the risk of cer-
vical dysplasia on a follow-up cervical biopsy. We
previously reported a 4% initial equivocal hrHPV test rate
and the subsequent conversion of 97.4% of those tests to
positive at the time of retesting.19 This number is higher
than that presented in the manufacturer’s packaging insert
when examining the final hrHPV positive rate after test-
ing equivocal samples. The manufacturer found a subse-
quent final positive rate of 177 of 219 samples (81%)
when using PreservCyt as the specimen medium and 127
FIGURE 5. Corresponding histologic diagnoses of samples
with unequivocal positive high-risk human papillomavirus
(hrHPV) tests (2-year follow-up [F/U]) after a cytologic diag-
nosis of atypical squamous cells of undetermined significance
were divided into cases falling above or below the median
chemiluminescence intensity. (A) Negative or reactive for
intraepithelial lesion or malignancy (NILM), cervical intraepi-
thelial neoplasia type I (CIN I), CIN II, or CIN III results were
expressed as the percentage of the biopsied cohort after
hrHPV test indicating chemiluminescence intensity below the
median. (B) NILM, cervical intraepithelial neoplasia type I
(CIN I), CIN II, or CIN III results were expressed as the per-
centage of the biopsied cohort after hrHPV test indicating
chemiluminescence intensity above the median.
FIGURE 6. Corresponding histologic diagnoses of samples
with unequivocal positive high-risk human papillomavirus
(hrHPV tests) (2-year follow-up [F/U]) after a cytologic diag-
nosis of atypical squamous cells of undetermined significance
were divided into cases falling above or below the median
chemiluminescence intensity. (A) Negative or reactive for
intraepithelial lesion or malignancy (NILM), cervical intraepi-
thelial neoplasia type I (CIN I), CIN II, or CIN III results were
expressed as the percentage of the biopsied cohort after an
hrHPV test indicating chemiluminescence below the median.
(B) NILM, CIN I, CIN II, or CIN III results were expressed as the
percentage of the biopsied cohort after an hrHPV test indi-
cated chemiluminescence above the median. HSIL indicates
high-grade squamous intraepithelial lesion; SIL, squamous
intraepithelial lesion.
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of 140 samples (91%) when using STM as the specimen
medium. On the basis of these data alone, and not follow-
up histology, the manufacturer recommends repeat test-
ing when specimens are preserved in PreservCyt but does
not recommend retesting when specimens are preserved
in STM due to the higher reproducibility of the latter.
Given that our retesting results demonstrated higher
reproducibility (ie, 97%) than either of the manufac-
turer’s tests, this lends strong support to the conclusion
that these tests do not need to be repeated. The current
study is comprised of samples preserved predominantly in
SurePath media, which has been shown to exhibit repro-
ducible results with the HC II hrHPV assay at the time of
retesting.17,22 SurePath is the predominant liquid-based
media (>97%) used for Pap tests at the reference institu-
tion, and therefore the preponderance of SurePath media
in the current study reflects the mix of Pap tests at the ref-
erence institution and not inherent qualities of either
SurePath or ThinPrep media.
The best rationale for treating these ‘‘equivocal’’ tests
as true-positive results can be found in examining the fol-
low-up histologic results. Thus, in addition to retesting,
we explored the 2-year histologic follow-up of cervical
biopsies associated with the ‘‘equivocal’’ tests to defini-
tively determine whether these tests differ with regard to
unequivocal positive hrHPV tests. Because dysplasia rates
may vary depending on the patient population being
served,10 we compared follow-up histology from ‘‘equivo-
cal’’ hrHPV tests with unequivocal positive hrHPV tests
in our laboratory. In our laboratory, the 2-year total risk
of dysplasia (CIN I/II/III) after an ASC-US Pap test was
43.5% or 45.9% of the biopsied cohort for ‘‘equivocal’’ or
positive hrHPV tests, respectively; and the 2-year risk of
high-grade dysplasia (CIN II/III) after an ASC-US Pap
test was 16.5% or 22.4% of the biopsied cohort for
‘‘equivocal’’ or positive hrHPV tests, respectively. As a
comparison, the ALTS trial reported a 2-year follow-up
rate of high-grade dysplasia of 26% in their biopsied
cohort, which was an average of the rates found among
the 4 participating institutions.10,11 Thus, on the basis of
the outcome of either hrHPV retesting or subsequent his-
tologic biopsy, data from the current study suggest that
hrHPV tests with an initial value >1.0 RLU/CO be
treated as an unequivocal positive hrHPV test, and that
repeat testing of these samples is unnecessary.
To our knowledge, few studies to date have exam-
ined the significance of ‘‘equivocal’’ hrHPV results
obtained from HC II.23 To our knowledge, the current
study is the first to provide a broad picture of the predic-
tive value of chemiluminescence intensity derived from
the HC II hrHPV test from the lowest, most equivocally
positive specimens to the highest values generally obtained
in laboratories. Although to the best of our knowledge no
other single institution has examined this on as broad a
scale, several other studies have examined the relation
between hrHPV viral load and subsequently detected cer-
vical dysplasia.24-29 The recently published series from
Sargent et al29 reported a reduced rate of high-grade dys-
plasia after an hrHPV test, with an RLU/CO value of
between 1 and 2 (ie, 9.2% vs 17.9% for an RLU/CO
value2.0), although their methodology differs consider-
ably from that of the current present study (eg, combining
‘‘borderline’’ and ‘‘mild’’ cytology). Nevertheless, the
indicated rate of 9.2% represents a nearly 5-fold risk com-
pared with that associated with negative hrHPV tests in
the study by Sargent et al.29 Using polymerase chain reac-
tion-based hrHPV detection, an increase in the viral load
of carcinogenic subtypes demonstrates a positive correla-
tion with cervical abnormalities in the general population
FIGURE 7. Corresponding relative light units (RLU)/cutoff
value (CO) ratios of high-risk human papillomavirus tests
from samples demonstrating atypical cells of undetermined
significance on cervical cytology and correlated with follow-
up cervical biopsies determined to be negative or reactive
for intraepithelial lesion or malignancy (NILM), cervical intrae-
pithelial neoplasia type I (CIN I), CIN II, and CIN III are shown.
The left bar in each pair corresponds to all cases (n ¼ 37 for
each group), whereas the right bar corresponds to the biop-
sied cohort.
High-Risk HPV DNA Test in Cervical Samples/Knoepp et al
Cancer Cytopathology August 25, 2010 215
(ie, when all Pap diagnoses are included),26 and the associ-
ation between type-specific HPV-16 viral load with CIN
III or cancer indicates a positive correlation in patients
with negative cervical cytology, but not those with ASC-
US cytology.24 When HC II was used to detect hrHPV
subtypes, no association was noted between increasing vi-
ral load and the risk of CIN III or cancer,27 although a
modest positive correlation was observed for CIN I.21
Further analysis of specimens gathered from the ALTS
trial demonstrated that higher hrHPV viral load is associ-
ated with a greater prevalence of multiple hrHPV sub-
types and exfoliated ASC-US/LSIL cells, but not
exfoliated ASC-H or HSIL cells.28 Thus, these studies
suggest that using hrHPV viral load to predict severe dys-
plasia in a clinically relevant setting is not possible. Data
from the current study lend further support to this hy-
pothesis, because we examined a highly clinically relevant
population (ie, a population with hrHPV positivity and
ASC-US cytology) and found no correlation with viral
load and the presence or severity of subsequently detected
dysplasia. We chose to divide patients evenly into either
halves or quartiles based on HC II chemiluminescence in-
tensity and found no significant difference between either
low-grade or high-grade dysplasia. Other methods of seg-
regating samples based on viral load (eg, an RLU/CO
value >1000) also failed to demonstrate a correlation
among the current study data, although our dataset for
specimens with a RLU/CO value >1000 was small
because such specimens comprise a small subset of posi-
tive hrHPV tests (ie, 6% in the current series). In addi-
tion, this subset has been examined exclusively in another
study and has been shown to be associated with a modest
increase of low-grade (CIN I) lesions, but not high-grade
lesions (ie, CIN II or above).21 Presumably, low-grade
dysplasias may demonstrate a higher viral load given that
these infections are productive, nonintegrated infections,
and active viral replication is taking place. The results of
the current study cannot fully address this theory because
we were unable to ascertain the presence of absence of
CIN I in those cases in which a CIN II or CIN III lesion
was detected; thus, CIN I lesions may be found in any or
all cases demonstrating CIN II or CIN III. The histologic
results of each biopsy were reported based on the highest
grade of dysplasia present as opposed to all grades of dys-
plasia that were present. In addition, colposcopically
directed biopsies are aimed at sampling the highest grades
of dysplasia versus detecting all areas of low-grade dyspla-
sia that may be present. Thus, the complex andmost likely
multiple opposing sets of biologic principals affecting the
association between viral load and dysplasia are difficult
to dissect in the current study. However, the relevant asso-
ciation between viral load and high-grade dysplasia in
clinically relevant samples is not difficult to dissect: the
results of the current study strongly refute the belief that
viral load can predict the degree or presence of high-grade
dysplasia in histologic cervical samples after an abnormal
Pap test.
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